Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 63-2521 in chronic thromboembolic pulmonary hypertension
NL-OMON37288Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Bayer. Primary endpoint: Change from baseline in 6-minute walking distance after 16 weeks. Started Aug 2010; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON37288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37288.